Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

SURMOUNT-CN

Eli Lilly · Phase 3 · Completed · Enrollment 210

NCT05024032

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

X axis: threshold category. Y axis: participants reaching threshold, %.

92.6529.4191.43
≥5%
83.8214.7170
≥10%
72.062.9448.57
≥15%
≥20%
Show as table
Arm≥5%≥10%≥15%≥20%
10 Milligrams (mg) Tirzepatiden/rn/rn/rn/r
15 mg Tirzepatide92.65%83.82%72.06%n/r
Placebo29.41%14.71%2.94%n/r
10 mg Tirzepatide91.43%70%48.57%n/r

Not shown

  • 10 Milligrams (mg) Tirzepatide: endpoint not reported